Agilent Technologies' ($A) ACCE composite score moved from 48 to 66, a delta of +18 points. That is a meaningful single-step move — large enough to shift $A from a below-average rating into solidly positive territory. The stock currently trades at $137.37, against an analyst consensus target of $161.31, implying roughly 17% upside from here.
What likely drove the move
ACCE composite scores draw on four subscore families: growth, value, quality, and momentum. An 18-point jump typically reflects improvement across more than one of them. Here is what the live data suggests:
Growth is the most obvious candidate. Year-over-year earnings are up 60.0% and revenue grew 10.0% over the same period. A 60% earnings jump is hard to ignore in any scoring model. If that figure came in ahead of prior estimates or marked an acceleration from recent quarters, the growth subscore would have moved sharply higher.
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
Value also looks more constructive than it might at first appear. The trailing P/E sits at 27.3, which is not cheap in absolute terms, but the forward P/E drops to 20.5. That compression — roughly 25% lower on a forward basis — signals that analysts expect continued earnings expansion. A tightening forward multiple relative to peers can lift a value subscore even when the trailing multiple looks stretched.
Quality feeds off earnings consistency, margin direction, and balance sheet health. A 60% earnings increase, if accompanied by margin expansion rather than just revenue leverage, would register positively here. We do not have margin data in this update, but the earnings growth rate relative to the 10% revenue growth rate suggests the company is doing more with each dollar of sales.
Momentum captures price and estimate trends. At $137.37 with a $161.31 analyst target, there is a meaningful gap between current price and where the Street thinks fair value sits. If estimate revisions have been trending upward alongside the earnings beat, momentum subscores would follow.
What it means
A score of 66 puts $A in the upper third of ACCE-rated Healthcare names. The 0.8% dividend yield is modest but adds a small income component to the total return picture. The gap between the current price and the $161.31 analyst target, combined with a market cap of $38.25B, gives this name enough size and liquidity to be relevant across a range of portfolio strategies.
The score move is a signal worth watching, not a guarantee. One strong earnings period can lift subscores quickly, and the next data cycle will test whether the improvement holds. Track $A's live score and price at acceinvestments.com/stocks/A.
See the full picture, free
ACCE scores thousands of stocks across six valuation models, with fair value, conviction and the full thesis on every name. Start free, no card required.
